Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Technology & Pipeline
  • Governance
  • Investors
  • Media
  • Contact
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Technology & Pipeline
    • XR Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Pipeline
      • Cantrixil
      • Docetaxel Micellar
    • Animal Health
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact
May 25, 2023

Annual General Meeting 2023

Annual General Meeting in Vivesto AB was held at 9 a.m. CEST on Thursday, 25 May 2023, at Gustav III:s Boulevard 42, ground floor, SE-169 73 Solna, Sweden.

Documents

  • Minutes AGM 2023 – Vivesto AB
    Swedish May 25, 2023
  • Notice Of Annual General Meeting 2023 Vivesto AB
    English April 25, 2023
  • Proxy form – Vivesto AB
    English April 25, 2023
  • Postal voting form AGM 2023 – Vivesto AB
    English April 25, 2023
  • Information about proposed Board members AGM 2023 – Vivesto AB
    English April 25, 2023
  • The proposal of the Board of Directors for resolution on adoption of an incentive programme for certain employees
    Swedish April 25, 2023
  • Auditor’s opinion as to whether the guidelines on remuneration of senior executives have been followed
    English April 25, 2023
  • The Nomination Committee’s reasoned opinon AGM 2023 – Vivesto AB
    English April 25, 2023
  • The Nomination Committee’s proposals AGM 2023 – Vivesto AB
    English April 25, 2023
  • Remuneration report 2022 – Vivesto AB
    English April 25, 2023
  • Press release – Report from Annual General Meeting in Vivesto AB
    English May 25, 2023

Share this page

Calendar

  • August 12, 2025
    Interim report Q2 2025
  • November 11, 2025
    Interim report Q3 2025
  • February 12, 2026
    Interim report Q4 2025
All events
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
Vivesto logo
  • About Us
  • Technology & Pipeline
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Box 3061
169 03 Solna, Sweden
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com